* [ ] 4-1BB (CD137)
* [ ] Adenosine
* [ ] Adoptive cell transfer
* [ ] Adaptive resistance
* [ ] AFP serum level
* [ ] AKT
* [ ] Alpha-fetoprotein (AFP)
* [ ] Angiogenesis
* [ ] Antigen loss
* [ ] Antigen presentation
* [ ] Anti-angiogenic therapy
* [ ] Anti-CTLA-4 therapy
* [ ] Anti-PD-1 therapy
* [ ] Anti-PD-L1 therapy
* [ ] Anergic T cells
* [ ] Arginase
* [ ] Arginase-1 (ARG1)
* [ ] Atezolizumab
* [ ] B cells
* [ ] B cell receptor (BCR)
* [ ] B7-H3
* [ ] B7-H4
* [ ] BRAF mutation
* [ ] Breast cancer
* [ ] BTLA
* [ ] Cancer stem cells
* [ ] Cancer vaccines
* [ ] Cancer-associated fibroblasts (CAFs)
* [ ] Cancer-associated neutrophils (CANs)
* [ ] CAR-T cell therapy
* [ ] Caspase-3
* [ ] Caspase-8
* [ ] CCL2
* [ ] CCL5
* [ ] CD3
* [ ] CD4
* [ ] CD4⁺ T cells
* [ ] CD8
* [ ] CD8⁺ T cells
* [ ] CD11b
* [ ] CD14
* [ ] CD25
* [ ] CD28
* [ ] CD31
* [ ] CD33
* [ ] CD39
* [ ] CD40
* [ ] CD40L
* [ ] CD56
* [ ] CD68
* [ ] CD73
* [ ] CD80
* [ ] CD86
* [ ] CD137
* [ ] CD163
* [ ] CD206
* [ ] Central memory T cells
* [ ] Chemokines
* [ ] Chimeric antigen receptor (CAR) constructs
* [ ] Chronic hepatitis
* [ ] Chronic inflammation
* [ ] Circulating tumor cells (CTCs)
* [ ] Circulating tumor DNA (ctDNA)
* [ ] c-Myc
* [ ] COX-2
* [ ] Colorectal cancer
* [ ] Collagen
* [ ] Combination immunotherapy
* [ ] Conventional dendritic cells (cDC1)
* [ ] Conventional dendritic cells (cDC2)
* [ ] CTLA-4
* [ ] CTNNB1 mutation
* [ ] Cytokines
* [ ] Cytotoxic T lymphocytes (CTLs)
* [ ] Dendritic cells (DCs)
* [ ] DNA methyltransferases (DNMTs)
* [ ] Dual checkpoint blockade
* [ ] Durvalumab
* [ ] Effector memory T cells
* [ ] EGF
* [ ] EGFR
* [ ] Endothelial cells
* [ ] ERK1/2
* [ ] Exhausted T cells
* [ ] Exosomes
* [ ] Extracellular matrix (ECM)
* [ ] Extracellular vesicles (EVs)
* [ ] FAP
* [ ] FGF
* [ ] FGFR
* [ ] Fibronectin
* [ ] Fibrosis
* [ ] FOXP3
* [ ] Gastric cancer
* [ ] Galectin-9
* [ ] GATA3
* [ ] GM-CSF
* [ ] Glypican-3 (GPC3)
* [ ] GLUT1
* [ ] Granulocyte-macrophage colony-stimulating factor
* [ ] HCC (Hepatocellular carcinoma)
* [ ] HDACs
* [ ] Hepatic stellate cells
* [ ] Hepatitis B virus (HBV)
* [ ] Hepatitis C virus (HCV)
* [ ] HER2
* [ ] HGF
* [ ] HIF-1α
* [ ] Histone deacetylases
* [ ] Hyaluronic acid
* [ ] Hypoxia
* [ ] ICAM-1
* [ ] ICOS
* [ ] IDO
* [ ] IFN-α
* [ ] IFN-β
* [ ] IFN-γ
* [ ] IL-1
* [ ] IL-2
* [ ] IL-4
* [ ] IL-6
* [ ] IL-8
* [ ] IL-10
* [ ] IL-12
* [ ] IL-17
* [ ] IL-18
* [ ] IL-21
* [ ] IL-22
* [ ] IL-23
* [ ] IL-27
* [ ] Immune checkpoint upregulation
* [ ] Immune evasion
* [ ] Immune infiltration score
* [ ] Immunosuppression
* [ ] Indoleamine 2,3-dioxygenase (IDO)
* [ ] Integrins
* [ ] Interferon-gamma
* [ ] JAK1
* [ ] JAK2
* [ ] JAK/STAT pathway
* [ ] KRAS mutation
* [ ] Kupffer cells
* [ ] LAG-3
* [ ] Laminin
* [ ] Lactate
* [ ] Lenvatinib
* [ ] Liver cirrhosis
* [ ] Liver fibrosis
* [ ] Lung cancer
* [ ] Lymphocyte activation gene-3
* [ ] MAPK pathway
* [ ] Mast cells
* [ ] Matrix metalloproteinases (MMPs)
* [ ] MDSCs
* [ ] MEK
* [ ] Melanoma
* [ ] Memory T cells
* [ ] Mesenchymal stem cells
* [ ] Metastasis
* [ ] Microsatellite instability (MSI)
* [ ] Microvesicles
* [ ] MMP-2
* [ ] MMP-9
* [ ] Monocytes
* [ ] mTOR
* [ ] Myeloid-derived suppressor cells
* [ ] NAFLD
* [ ] NASH
* [ ] Neoantigens
* [ ] Neoantigen vaccine
* [ ] Neutrophils
* [ ] NF-κB
* [ ] NF-κB pathway
* [ ] Nivolumab
* [ ] NK cells
* [ ] NKp30
* [ ] NKp46
* [ ] NKG2D
* [ ] Nitric oxide (NO)
* [ ] Non-alcoholic fatty liver disease
* [ ] Non-alcoholic steatohepatitis
* [ ] NY-ESO-1
* [ ] Oncolytic virus therapy
* [ ] OX40
* [ ] OX40L
* [ ] Pancreatic cancer
* [ ] PD-1
* [ ] PD-L1
* [ ] PD-L2
* [ ] PDGF
* [ ] Pembrolizumab
* [ ] Pericytes
* [ ] Personalized immunotherapy
* [ ] PI3K
* [ ] PI3K/AKT pathway
* [ ] Plasma cells
* [ ] Plasmacytoid dendritic cells
* [ ] Primary resistance
* [ ] Prostaglandin E2
* [ ] Prostate cancer
* [ ] Reactive oxygen species (ROS)
* [ ] Regorafenib
* [ ] Regulatory T cells (Tregs)
* [ ] Renal cell carcinoma
* [ ] RORγt
* [ ] Selectins
* [ ] SMAD2
* [ ] SMAD3
* [ ] SMAD4
* [ ] Sorafenib
* [ ] STAT1
* [ ] STAT3
* [ ] STAT5
* [ ] Stromal compartment
* [ ] T cell exhaustion
* [ ] T cell receptor (TCR)
* [ ] TAMs (Tumor-associated macrophages)
* [ ] TCR-T therapy
* [ ] Tenascin-C
* [ ] TGF-β
* [ ] TGF-β signaling pathway
* [ ] Th1 cells
* [ ] Th2 cells
* [ ] Th17 cells
* [ ] TIGIT
* [ ] TIM-3
* [ ] Tissue-resident memory T cells
* [ ] TIL therapy
* [ ] TNF-α
* [ ] TP53 mutation
* [ ] Tryptophan 2,3-dioxygenase (TDO)
* [ ] Tumor heterogeneity
* [ ] Tumor microenvironment (TME)
* [ ] Tumor mutational burden (TMB)
* [ ] Tumor-associated antigens (TAAs)
* [ ] VEGF
* [ ] VEGF signaling pathway
* [ ] VEGF-A
* [ ] VEGFR-2
* [ ] VISTA
* [ ] Viral hepatitis
* [ ] Wnt/β-catenin pathway
* [ ] β-catenin
